Fungitell® References

  1.   Pfaller, M.A., (2009) Focus on Fungal Infection 19 Proceedings.
  2.   Reboli, A.C., (2009) Focus on Fungal Infection 19 Proceedings.
  3.   Kumar, A et al. Poster 2174 ICAAC 2007
  4.   Odabasi Z., Mattiuzzi G., Estey E., Kantarjian H., Saeki F., Ridge R., Ketchum P., Finkelman M., Rex J. and Ostrosky-Zeichner L. (2004) Beta-D-Glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Clinical Infectious Diseases. 39:199-205.
  5.   Ostrosky-Zeichner L., Alexander B., Kett D., Vazquez J., Pappas P., Saeki F., Ketchum P., Wingard J., Schiff R., Tamura H., Finkelman M., and Rex J. (2005) Multicenter clinical evaluation of the (1→3)-β-D-Glucan assay as as aid to diagnosis of fungal infections in humans. Clin. Inf. Dis. 41: 654-659.
  6.   Pazos C., Ponton J., and Del Palacio A. (2005) Contribution of (1→3)-β-D-Glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: A comparison with serial screening for circulating galactomannan. J. Clin. Micro. 43(1): 299-305.
  7.   Pazos, C., Moragues, M-D., Quindos, G., and del Palacio, A. (2006) Diagnostic potential of (1→3)-β-D-Glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Re. Iberoam Micol. 23: 209-215.
  8.   Ellis, M., Ramadi, B., Finkelman, M., Hedstrom, U., Kristenson, J., Ali-Zadeh, H., and Klingspor, L. (2007) Assessment of the clinical utility of serial β-D-Glucan concentrations in patients with persistent neutropenic fever. J. Med. Microbiol. 57: 287-95.
  9.   Morrell, M., Fraser, V., and Kollef, M. (2005) Delaying the empiric treatment of Candida bloodstream infection until positive culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents. Chemother. 49: 3640-3645.
  10.   Enoch et al., (2006) JMM 55:809-818.
  11.   Marty, F. M., Koo, S., Bryar,and J., Baden, L.R. (2007) (1→3)-β-D-Glucan assay positivity in patients with Pneumocystis (carinii) jirovecii pneumonia. Ann. Int. Med. 147: 70-72.
  12.   Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A (2008) Contribution of the (1→3)-β-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections. J. Clin. Micro. 36: 1009-1013.
  13.   Nucci, M., Nouér, S.A., Esteves, P., Guimarães, T., Breda, G., Grassi de Miranda, B., Queiroz-Telles, F., and Colombo, A.L., Discontinuation of empirical antifungal therapy in ICU patients using (1→3)-β-D-glucan, Journal of Antimicrobial Chemotherapy Advance Access. published June 10, 2016.

a. Products are free of interfering glucans
b. Available from Associates of Cape Cod, Inc.

*Cryptocuccus, Zygomycetes (such as Absidia, Mucor and Rhizopus) and Blastomyces dermatitidis (infective yeast form) are known to have little or no (1→3)-β-D-Glucan and thus, glucan is not detected during infection with these organisms.